

Cristina Florean

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11051293/publications.pdf>

Version: 2024-02-01

18
papers

923
citations

623734

14
h-index

888059

17
g-index

19
all docs

19
docs citations

19
times ranked

1619
citing authors

#	ARTICLE	IF	CITATIONS
1	Immune-modulating and anti-inflammatory marine compounds against cancer. <i>Seminars in Cancer Biology</i> , 2022, 80, 58-72.	9.6	24
2	Bioactive Bromotyrosine Derivatives from the Pacific Marine Sponge <i>Suberea clavata</i> (Pulitzer-Finali), <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf</i>	4.6	12
3	Identification of a novel quinoline-based DNA demethylating compound highly potent in cancer cells. <i>Clinical Epigenetics</i> , 2019, 11, 68.	4.1	30
4	Natural Compounds as Epigenetic Modulators in Cancer. <i>Proceedings (mdpi)</i> , 2019, 11, .	0.2	0
5	Redox biology of regulated cell death in cancer: A focus on necroptosis and ferroptosis. <i>Free Radical Biology and Medicine</i> , 2019, 134, 177-189.	2.9	95
6	Synergistic AML Cell Death Induction by Marine Cytotoxin (+)-1(R), 6(S), 1â€™™(R), 6â€™™(S), 11(R), 17(S)-Fistularin-3 and Bcl-2 Inhibitor Venetoclax. <i>Marine Drugs</i> , 2018, 16, 518.	4.6	16
7	Discovery and characterization of Isofistularin-3, a marine brominated alkaloid, as a new DNA demethylating agent inducing cell cycle arrest and sensitization to TRAIL in cancer cells. <i>Oncotarget</i> , 2016, 7, 24027-24049.	1.8	54
8	Editorial (Thematic Issue: Novel Pharmaceutical Approaches by Natural Compound-Derived Epigenetic) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf</i> <i>Medicinal Chemistry</i> , 2015, 16, 677-679.	2.1	3
9	Epigenetic alterations as a universal feature of cancer hallmarks and a promising target for personalized treatments. <i>Current Topics in Medicinal Chemistry</i> , 2015, 16, 745-776.	2.1	35
10	Selective Non-nucleoside Inhibitors of Human DNA Methyltransferases Active in Cancer Including in Cancer Stem Cells. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 701-713.	6.4	111
11	Chromatin-modifying agents in anti-cancer therapy. <i>Biochimie</i> , 2012, 94, 2264-2279.	2.6	67
12	Class IIa HDACs: from important roles in differentiation to possible implications in tumorigenesis. <i>Journal of Cellular and Molecular Medicine</i> , 2011, 15, 1833-1846.	3.6	86
13	Epigenomics of leukemia: from mechanisms to therapeutic applications. <i>Epigenomics</i> , 2011, 3, 581-609.	2.1	97
14	Ubiquitin-dependent degradation of HDAC4, a new regulator of random cell motility. <i>Molecular Biology of the Cell</i> , 2011, 22, 278-289.	2.1	57
15	Presenilinâ€™2 dampens intracellular Ca ²⁺ stores by increasing Ca ²⁺ leakage and reducing Ca ²⁺ uptake. <i>Journal of Cellular and Molecular Medicine</i> , 2009, 13, 3358-3369.	3.6	73
16	Recombinant Differential Anchorage Probes that Tower over the Spatial Dimension of Intracellular Signals for High Content Screening and Analysis. <i>Analytical Chemistry</i> , 2009, 81, 9590-9598.	6.5	8
17	High content analysis of Î³-secretase activity reveals variable dominance of presenilin mutations linked to familial Alzheimer's disease. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2008, 1783, 1551-1560.	4.1	19
18	Presenilin mutations linked to familial Alzheimer's disease reduce endoplasmic reticulum and Golgi apparatus calcium levels. <i>Cell Calcium</i> , 2006, 39, 539-550.	2.4	136